Amylyx Pharmaceuticals, Inc.
AMLX
$3.63
-$0.045-1.23%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -77.06% | -33.22% | 55.71% | 324.95% | 1,612.94% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -77.06% | -33.22% | 55.71% | 324.95% | 1,612.94% |
Cost of Revenue | 48.88% | 137.06% | 138.03% | 165.35% | 59.29% |
Gross Profit | -162.22% | -158.98% | -66.97% | 1,219.25% | 406.09% |
SG&A Expenses | -39.30% | -15.53% | 14.02% | 39.59% | 48.16% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 17.58% | 55.20% | 74.55% | 92.30% | 52.96% |
Operating Income | -911.12% | -3,422.89% | -119.12% | 47.76% | 119.27% |
Income Before Tax | -656.45% | -4,620.35% | -129.99% | 55.79% | 127.48% |
Income Tax Expenses | -107.82% | -48.52% | 58.10% | 1,087.34% | 549.35% |
Earnings from Continuing Operations | -712.42% | -14,232.14% | -127.80% | 52.27% | 124.84% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -712.42% | -14,232.14% | -127.80% | 52.27% | 124.84% |
EBIT | -911.12% | -3,422.89% | -119.12% | 47.76% | 119.27% |
EBITDA | -886.73% | -3,912.70% | -119.99% | 48.31% | 119.86% |
EPS Basic | -705.81% | -42,510.00% | -100.06% | 57.89% | 121.36% |
Normalized Basic EPS | -795.39% | -11,279.09% | -108.16% | 55.64% | 119.14% |
EPS Diluted | -734.56% | -16,371.12% | -97.18% | 56.86% | 120.37% |
Normalized Diluted EPS | -823.85% | -49,272.00% | -106.26% | 54.66% | 118.38% |
Average Basic Shares Outstanding | 1.41% | 1.73% | 4.97% | 8.43% | 14.95% |
Average Diluted Shares Outstanding | -2.63% | -1.08% | 3.73% | 9.42% | 19.72% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |